Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Notes Payables (2016 - 2025)

Historic Notes Payables for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to $13.6 million.

  • Northwest Biotherapeutics' Notes Payables rose 7909.46% to $13.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.6 million, marking a year-over-year increase of 7909.46%. This contributed to the annual value of $14.2 million for FY2024, which is 25968.56% up from last year.
  • As of Q3 2025, Northwest Biotherapeutics' Notes Payables stood at $13.6 million, which was up 7909.46% from $16.3 million recorded in Q2 2025.
  • Over the past 5 years, Northwest Biotherapeutics' Notes Payables peaked at $20.0 million during Q3 2022, and registered a low of $2.2 million during Q1 2021.
  • In the last 5 years, Northwest Biotherapeutics' Notes Payables had a median value of $9.9 million in 2022 and averaged $10.8 million.
  • Its Notes Payables has fluctuated over the past 5 years, first tumbled by 7867.82% in 2021, then skyrocketed by 43514.96% in 2022.
  • Over the past 5 years, Northwest Biotherapeutics' Notes Payables (Quarter) stood at $7.1 million in 2021, then skyrocketed by 116.82% to $15.4 million in 2022, then crashed by 74.39% to $3.9 million in 2023, then soared by 259.69% to $14.2 million in 2024, then fell by 4.34% to $13.6 million in 2025.
  • Its Notes Payables was $13.6 million in Q3 2025, compared to $16.3 million in Q2 2025 and $19.6 million in Q1 2025.